ARCALIS will have an exhibition booth at the 13th International mRNA Health Conference.
ARCALIS will have our exhibition booth at the International mRNA Health Conference, to be held at the InterContinental Berlin from November 11 (Tue) to 13 (Thu), 2025. We warmly welcome all conference participants to visit us.
【Event details】
Conference: 13th International mRNA Health Conference
Website: https://mrna-conference.com/
Date: November 11th (Tue) -13th (Thu), 2025
Venue: InterContinental Berlin
Access: https://www.berlin.intercontinental.com
【Invited talk】
Date: November 13th, Day 3, 09:50 am – 09:55 am
Title: Establishing Japan’s mRNA Ecosystem: Advancing Next-Generation mRNA Vaccines
Presenter: Hamid Trimech (Manager, Business Development)
【Exhibition booth】Booth number: 22
mRNA therapeutics are transforming the fields of vaccines, immunotherapies, and protein replacement therapies, thanks to their rapid design flexibility and highly efficient protein expression. ARCALIS, Inc. delivers seamless, end-to-end services from mRNA design through to large-scale commercial manufacturing. In partnership with its group company, Axcelead Drug Discovery Partners, Inc., ARCALIS also provides comprehensive support from mRNA drug development and manufacturing to preclinical studies, enabling smooth progress toward IND submission. ARCALIS’s capabilities have been validated through the successful commercial production of the self-amplifying mRNA (saRNA) COVID-19 vaccine KOSTAIVE®. Building on this achievement, the company introduces a suite of innovative technologies that accelerate next-generation mRNA medicine development:
- A proprietary saRNA platform enabling sustained and efficient protein expression for drug discovery support.
- HARNATM, a machine learning-based codon optimization tool co-developed with Hitachi, which significantly enhances in vivo protein expression.
- An advanced T7 RNA polymerase engineered to minimize dsRNA impurities.
- A novel P1 nuclease-based assay that provides highly accurate evaluation of capping efficiency.
With these cutting-edge innovations, ARCALIS is committed to advancing safer, more effective mRNA medicines and driving the future of RNA therapeutics.